Hong Kong's Essex Bio-Technology H1 revenue falls
Hong Kong's Essex Bio-Technology H1 revenue falls
Overview
Hong Kong biopharma firm's H1 turnover fell 10.5% yr/yr to HK$784.7 mln
Net profit for H1 dropped 32.2% yr/yr, with EPS at HK19.53 cents
Company cut interim dividend to HK5.0 cents from HK7.0 cents last year
Outlook
Company did not provide specific financial guidance or outlook for future periods
Result Drivers
HIGHER EXPENSES - Administrative costs, rose yr/yr and contributed to lower profitability
MARGIN DECLINE - Gross profit margin and net profit margin fell compared to prior yr
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| HK$784.69 mln |
|
Analyst Coverage
The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 6 three months ago
Reuters Recommended Reads
Aug 3 - China's WuXi AppTec H1 revenue rises, raises 2026 guidance
Aug 4 - Pfizer Q2 results beat; raises 2026 revenue outlook
Aug 4 - BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share